Viewpoint
Zachary Hafner
It’s funny how certain buzzwords and phrases catch on in health care. We’ve seen HMO come and go, ACO start strong then fade, and population health struggle to become mainstream. Nowadays, it’s all about value-based care. Ask any industry insider what that means, and you’re likely to get a response…
News & Commentary
A GAO report notes that HHS under the Trump administration cut money for paid advertising for the 2018 open enrollment period by 90%; from the $100 million for the 2017 enrollment period, down to $10 million for 2018. TV advertising went from $26.6 million under the Obama administration’s final year allocation to zero under President Trump.
Governing Health Care
Richard Mark Kirkner
Bereft of his own connections, President Trump recruited from conservative think tanks to fill health care positions in his administration. Many of them have Koch brother connections, and their agendas often run counter to Trump campaign rhetoric—and his impulses.
News Wire
It’s the latest effort in damage control in a scandal that’s embarrassed Harvard Medical School and Brigham and Women’s Hospital.
Growing opioid crisis fueling suicide increase according to study
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Only 18.7% of Patients Treated Had Uveitis Recurrence
Team Trump
Richard Mark Kirkner
ProPublica has identified key personnel in the Trump health policy apparatus.
Richard Mark Kirkner
Here’s a list, by no means exhaustive, of think tanks that have developed conservative and libertarian policies and principles in health care
In 1971, college campuses were in turmoil over the war in Vietnam and social norms were undergoing seismic changes. Against this backdrop, Lewis F. Powell Jr., a corporate lawyer whom President Richard Nixon would soon nominate to the Supreme Court, sent a confidential memo to Eugene Sydnor Jr., chair…
CURRENT ISSUE October 2018

Medicare for All? Or Just for More?

With mid-terms next month, Democrats think that they’ve got a winning issue. Our cover story points out that Medicare expansion plans come in two basic flavors: a true single-payer approach, or giving people the option to buy into a public plan that competes with private insurers. None other than Howard Dean, MD, offers a reality check by pointing out that, “no one likes to tell anybody how they’re going to pay for any of it.”

And talk about strange bedfellows. President Trump, who came to power as an “outsider,” has had to fill many health care policy positions with people connected to the Koch brothers.

We also look at multiple sclerosis, a managed care nightmare. The escalating prices of the medications used to treat this unpredictable disease are undercut by questions regarding their cost effectiveness.

UPCOMING MEETINGS
Nashville, TN
November 07-09, 2018
Dallas, TX
November 12-13, 2018
The weird economics of autoimmune disease
Charlotte Huff
It is often an on-again, off-again disease, distressing partly because it is so un­predictable. It may defy the conventional wisdom about adherence and early treatment. And escalating prices have undercut cost-effectiveness arguments for the drugs that can keep it in check. Multiple sclerosis is a managed care nightmare.
Medication Management
Thomas Reinke
Pharma and Trump administration officials decry them as backroom deals. But payers and PBMs say rebates are an important negotiating tool with drugmakers. Take it away and drug expenditure will go up even faster.
Viewpoint
Maggie Alston
Bruce Pyenson
They can work, but pharma will need to master the intricacies of adherence metrics, real-world outcomes, and sampling.